Table 1.

Increased Numbers of Human Progenitors Detected in Secondary Recipients of Cells from Primary Recipients Administered Human SF, IL-3, GM-CSF, and Ep

Exp. No. of 1° Recipients per Group Proportion of BM Cells from 1° Recipients Injected into 2° Recipients Time of Assessment of 1° Recipients (wks posttransplant) Human Cell Type Evaluated in 2° Recipients 1° Recipients Administered no GF 1° Recipients Administered 4 GF × 6
No. of Positive 2° RecipientsNo. of Cells per 2° Recipients*No. of Positive 2° Recipients No. of Cells per 2° Recipients*
1† 2  18%  6  CFC  1/2  4200  2/2 850, 4600  
    LTC-IC  0/2   1/2  12 
2  3  25%  6  CFC  0/3   2/3  870, 1600 
3  3  18%  4  CFC  0/4   4/4  700, 480, 1700, 3300  
4  4  18%  6  CFC  1/4   150  4/4 970, 20000, 490, 620  
    LTC-IC  0/4   4/4 4, 70, 1, 12 
Exp. No. of 1° Recipients per Group Proportion of BM Cells from 1° Recipients Injected into 2° Recipients Time of Assessment of 1° Recipients (wks posttransplant) Human Cell Type Evaluated in 2° Recipients 1° Recipients Administered no GF 1° Recipients Administered 4 GF × 6
No. of Positive 2° RecipientsNo. of Cells per 2° Recipients*No. of Positive 2° Recipients No. of Cells per 2° Recipients*
1† 2  18%  6  CFC  1/2  4200  2/2 850, 4600  
    LTC-IC  0/2   1/2  12 
2  3  25%  6  CFC  0/3   2/3  870, 1600 
3  3  18%  4  CFC  0/4   4/4  700, 480, 1700, 3300  
4  4  18%  6  CFC  1/4   150  4/4 970, 20000, 490, 620  
    LTC-IC  0/4   4/4 4, 70, 1, 12 
*

Total CFC or LTC-IC per mouse BM (individual values for each positive 2° recipient).

†

The results of this first experiment are taken from 10.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal